Stanford University
Showing 1,251-1,300 of 2,211 Results
-
Helena McCombie
Chief of Staff - Office of the Chair, Medicine
Current Role at StanfordChief of Staff - Office of the Chair at Stanford University School of Medicine Department of Medicine
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). Current studies include: 1) the impact of macronutrient composition on metabolism, DM2 and CVD; 2) comparison of different weight loss diets on metabolism and CVD risk reduction ; 3) role of adipocytes and adipose tissue immune cells in modulating insulin resistance; 4) use of continuous glucose monitoring and multi-omics to define metabolic phenotype and precision diets
-
Bruno Medeiros
Adjunct Clinical Associate Professor, Medicine - Hematology
Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
-
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health care. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily, and she is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies. She also directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC). -
Hector Rodrigo Mendez
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Hector Rodrigo Mendez is a Medical Geneticist from Argentina. Rodrigo completed a residency program in Medical Genetics at Centro Nacional de Genetica Medica – ANLIS (Buenos Aires, Argentina) and a Master’s program in Medical Molecular Biology at Buenos Aires University.
Rodrigo continued his scientific career at a German Genomic Start-up, working as a human geneticist and providing his experience in rare disorders, genomic data (WGS/WES/gene panels) analysis, variant interpretation, and its integration with a deep focus on genotype-phenotype correlation.
Rodrigo’s areas of expertise are rare disorders, NGS technology, Whole Genome Sequencing analysis, and ACMG interpretation guidelines, and his research aims are:
- Collection and analysis of clinical data through deep-learning phenotyping approaches.
- Multi-omic data integration to elucidate complex and rare genetic disorders.
- International collaborations to break down barriers to research participation amongst those who have been under-represented.
At Stanford University, under the supervision of Dr. Matthew Wheeler, he is conducting his postdoctoral research studies to achieve his scientific goals. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Thomas Charles Merigan M.D.
George E. and Lucy Becker Professor of Medicine, Emeritus
Current Research and Scholarly InterestsI am now emeritus and only participate in university activities through advising my former trainees who have joined the faculty.
-
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Lekha Mikkilineni
Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)
BioDr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.
Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia.
Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.
Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.
Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences. -
David Miklos
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
-
Christina Milcarek
Executive Administrator, Med/Stanford Center for Clinical Research
Current Role at StanfordProviding executive support to:
Dr. Kenneth Mahaffey, Director, Stanford Center for Clinical Research (SCCR)
Toni Nunes, Director of Operations & Strategy, Stanford Center for Clinical Research (SCCR) -
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
Arnold Milstein
Professor of Medicine (General Medical Discipline)
Current Research and Scholarly InterestsDesign national demonstration of innovations in care delivery that provide more with less. Informed by research on AI-assisted clinical workflow, positive value outlier analysis and triggers of loss aversion bias among patients and clinicians.
Research on creation of a national index of health system productivity gain. -
Vijay Mirmira
Adjunct Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Mirmira believes that excellent communication leads to excellent care, and is dedicated to the health and well-being of his patients and their families. He is fluent in English, Hindi, Tamil and Kannada and has working knowledge of Urdu and Telugu. Apart from enjoying practicing the full scope of family medicine, Dr. Mirmira's special interests include diabetes and thyroid disorders, and pediatric illnesses. He likes to travel and read fiction in his free time.
-
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Maha Abdalla Mohamed, MD, FACP, FAST
Clinical Associate Professor, Medicine - Nephrology
BioDr. Mohamed is a board-certified, fellowship-trained nephrologist with the Kidney and Pancreas Transplant Program at Stanford Healthcare. She is a clinical associate professor in the Department of Medicine, Division of Nephrology.
Dr. Mohamed specializes in kidney and pancreas transplant outcomes and kidney transplant health equity. Conditions she treats include allografts rejection, recipient BK virus and CMV infection, and post-transplant lymphoproliferative disorder management. Dr. Mohamed is known for her personalized and comprehensive approach to patient care. She takes the time to understand her patients’ unique health needs and creates tailored care plans that fit their lifestyles.
Dr. Mohamed’s research interests include examining new approaches to improving kidney transplant long-term outcome including kidney transplant rejection and infection. She also seeks to develop better screening and monitoring guidance to help reduce post-transplant BK virus and CMV infection.
Dr. Mohamed’s published work can be found in peer-reviewed journals such as Clinical Transplantation, Transplant Infectious Disease and Transplantation. She has presented to her peers at international, national, and regional meetings, including at the American Transplant Congress and the American Society of Nephrology. She has also been invited to speak multiple times at King Faisal Hospital in Rwanda as well as in Kingdom of Saudi Arabia on topics like post-transplant lymphoproliferative disorder, update in kidney transplant rejection, and update in living-donor kidney transplantation.
Dr. Mohamed is a faculty fellow of Stanford Center for Innovation in Global Health, fellow of the American Society of Transplantation, a board of managers member of the AST Transplant Nephrology Fellowship Training Accreditation Program, member of the International Society of Nephrology and the American Society of Nephrology.